Gene Study for Infantile Onset Diabetes
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03169413 |
Recruitment Status : Unknown
Verified May 2017 by Shimaa Kamal, Assiut University.
Recruitment status was: Not yet recruiting
First Posted : May 30, 2017
Last Update Posted : May 31, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both.
According to American Diabetes Association diabetes can be classified into the following general categories: Type one diabetes (due to beta cell destruction, usually leading to absolute insulin deficiency), Type two diabetes (due to a progressive insulin secretory defect on the background of insulin resistance), Gestational diabetes mellitus and specific types of diabetes due to other causes, example monogenic diabetes syndromes (such as neonatal diabetes and maturity-onset diabetes of the young, diseases of the exocrine pancreas, and drug induced diabetes.
Condition or disease | Intervention/treatment |
---|---|
Study Genetic Basis of Infantile Onset Diabetes Mellitus | Genetic: Human Leucocytic antigen typing and mutation of adenosine triphosphate sensitive K channel gene in diabetic patients diagnosed under the age of one year. |

Study Type : | Observational |
Estimated Enrollment : | 100 participants |
Observational Model: | Case-Control |
Time Perspective: | Retrospective |
Official Title: | Human Leucocytic Antigen Typing and Mutation of Adenosine Triphosphate Sensitive Potassium Channel Gene in Diabetic Patients Diagnosed Under the Age of One Year. |
Estimated Study Start Date : | January 2018 |
Estimated Primary Completion Date : | January 2020 |
Estimated Study Completion Date : | August 2020 |

Group/Cohort | Intervention/treatment |
---|---|
cases
Fifty diabetic children diagnosed under the age of one year subjected to genetic analysis to study human leucocytic antigen haplotype class two (DR-DQ) and detection of mutations in the potassium channel, inwardly rectifying subfamily J member 11 gene encoding the Kir6.2 subunit of adenosine triphosphate sensitive potassium channel also possible risk factors associated with the disease.
|
Genetic: Human Leucocytic antigen typing and mutation of adenosine triphosphate sensitive K channel gene in diabetic patients diagnosed under the age of one year.
Gene study |
control one
Twenty five diabetic children diagnosed after the age of one year subjected to genetic study to study human leucocytic antigen and possible of presence of gene mutation of the potassium channel, inwardly rectifying subfamily J member 11 gene encoding the Kir6.2 subunit of adenosine triphosphate sensitive potassium channel and possible risk factors associated with disease .
|
Genetic: Human Leucocytic antigen typing and mutation of adenosine triphosphate sensitive K channel gene in diabetic patients diagnosed under the age of one year.
Gene study |
control two
Twenty five healthy children matched by age subjected to genetic study to study human leucocytic antigen and possible of presence of gene mutation of the potassium channel, inwardly rectifying subfamily J member 11 gene encoding the Kir6.2 subunit of adenosine triphosphate sensitive potassium channel and exposure to similar risk factors associated with disease .
|
Genetic: Human Leucocytic antigen typing and mutation of adenosine triphosphate sensitive K channel gene in diabetic patients diagnosed under the age of one year.
Gene study |
- Human Leucocytic antigen typing and mutation of adenosine triphosphate sensitive potassium channel gene in diabetic patients diagnosed under the age of one year. [ Time Frame: At time of diagnosis with diabetes under the age of one year ]Polymerase chain reaction / Deoxyribonucleic acid sequencing
- Rate of diabetes mellitus in patients under age of one year attending pediatric endocrinology unit in Pediatric assiut University Hospital [ Time Frame: Within two years ]Total coverage of all diabetic cases diagnosed under the age of one year
- dentification of possible demographic and environmental risk factors associated with increased risk of diabetes in diabetic patient under the age of one year. [ Time Frame: Within two years ]Identification of prenatal, perinatal, natal history,nutritional history, vaccination history and hygiene measures

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 1 Year to 3 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Diabetic patients with disease onset under the age of one year according to American Diabetes Association criteria 2016 which include:
- Fasting plasma glucose level at or above 7 millimol/Litre.
- Plasma glucose at or above 11.1 millimol/Litre two hours after a 1.75 gram/kilogram oral glucose load as in a glucose tolerance test.
- Symptoms of hyperglycemia and random plasma glucose at or above 11.1 millimol/Litre.
- Glycated hemoglobin at or above 48 millimol/mol.
Exclusion Criteria:
-Diabetic children with the disease onset above the age of one year.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03169413
Contact: Prof Hanaa Abdellatif Mohamed, MD | 01120096055 | Hae50@hotmail.com | |
Contact: Kotb Abbas Metwally, MD | 01003912599 | Kotb72@yahoo.com |
Responsible Party: | Shimaa Kamal, Principle Investigator, Assiut University |
ClinicalTrials.gov Identifier: | NCT03169413 |
Other Study ID Numbers: |
IDM |
First Posted: | May 30, 2017 Key Record Dates |
Last Update Posted: | May 31, 2017 |
Last Verified: | May 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Adenosine Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Arrhythmia Agents |
Vasodilator Agents Purinergic P1 Receptor Agonists Purinergic Agonists Purinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |